TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34711192

Group type: EXPERIMENTAL
Intervention: sugammadex 2 mg/kg
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: sugammadex 4 mg/kg
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: sugammadex 16 mg/kg
Number of subjects: 344

Group type: COMPARATOR
Intervention: neostigmine/glycopyrrolate
Number of subjects: 344
Study: 32164494

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 6979
Study: 33740965

Group type: EXPERIMENTAL
Intervention: Registered nurse/social educator
Number of subjects: 3693

Group type: EXPERIMENTAL
Intervention: Licensed practical nurse
Number of subjects: 3693

Group type: EXPERIMENTAL
Intervention: Reporting symptoms of psychological distress
Number of subjects: 3693

Group type: EXPERIMENTAL
Intervention: Intention to leave the job
Number of subjects: 3693

Group type: EXPERIMENTAL
Intervention: Poor attitudes towards people with dementia
Number of subjects: 3693

Group type: EXPERIMENTAL
Intervention: Poor quality of childhood
Number of subjects: 3693

Group type: EXPERIMENTAL
Intervention: Care-related conflicts
Number of subjects: 3693

Group type: EXPERIMENTAL
Intervention: Resident aggression
Number of subjects: 3693

Group type: EXPERIMENTAL
Intervention: Lack of support from a manager
Number of subjects: 3693
Study: 32037125

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 866

Group type: COMPARATOR
Intervention: Non-corticosteroids
Number of subjects: 866
Study: 33866311

Group type: EXPERIMENTAL
Intervention: Wet cupping plus 500 mg azithromycin 3 times/week for 12 weeks
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sham cupping plus 500 mg azithromycin 3 times/week for 12 weeks
Number of subjects: 103
Study: 35412430

Group type: EXPERIMENTAL
Intervention: Adjuvant irinotecan-based therapy (IFL)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Adjuvant fluorouracil/leucovorin (5‐FU/LV)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Adjuvant irinotecan-based therapy (IFL) in patients with unDCR1 and KRAS-wildtype tumours
Number of subjects: 400

Group type: COMPARATOR
Intervention: Adjuvant fluorouracil/leucovorin (5‐FU/LV) in patients with unDCR1 and KRAS-wildtype tumours
Number of subjects: 400
Study: 33350172

Group type: EXPERIMENTAL
Intervention: Competition condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cooperation condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Males in competitive situation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Males in cooperative situation
Number of subjects: 0
Study: 32452549

Group type: EXPERIMENTAL
Intervention: Lanadelumab 150 mg every 4 weeks
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Lanadelumab 300 mg every 4 weeks
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Lanadelumab 300 mg every 2 weeks
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Lanadelumab (all doses)
Number of subjects: 125
Study: 35343430

Group type: EXPERIMENTAL
Intervention: New sodium valproate formulation (epilenil 500-mg coated tablet)
Number of subjects: 0
Study: 33098330

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality game (Dreamland)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Tablet with video games (control group)
Number of subjects: 188
Study: 36165607

Group type: EXPERIMENTAL
Intervention: qPCR assay
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: nPCR assay
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: VDRL test
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Immunoblot test
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Treponemal tests (TT)
Number of subjects: 143
Study: 34030647

Group type: EXPERIMENTAL
Intervention: Competing risk nomogram for predicting cancer-specific survival (CSS)
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Competing risk nomogram for predicting CSS
Number of subjects: 839

Group type: COMPARATOR
Intervention: AJCC staging system
Number of subjects: 839
Study: 34555151

Group type: EXPERIMENTAL
Intervention: Regular meal pattern (14 days; 6 meals/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Irregular meal pattern (14 days; 3-9 meals/day)
Number of subjects: 9
Study: 32198794

Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 116
Study: 33561724

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 32290136

Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Strength + Endurance training (SE)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Adhering to physical activity recommendations (C)
Number of subjects: 119
Study: 35889944

Group type: EXPERIMENTAL
Intervention: HeLP-her intervention (four lifestyle sessions)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard antenatal care (control)
Number of subjects: 228
Study: 34781221

Group type: EXPERIMENTAL
Intervention: Traditional Swallowing Therapy (TST) and Neuromuscular Electrical Stimulation (NMES)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Traditional Swallowing Therapy (TST) and Kinesiology Taping (KT)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Traditional Swallowing Therapy (TST), Neuromuscular Electrical Stimulation (NMES), and Kinesiology Taping (KT)
Number of subjects: 37
Study: 32521473

Group type: EXPERIMENTAL
Intervention: Low-fidelity pelvic model
Number of subjects: 75

Group type: COMPARATOR
Intervention: High-fidelity computer-based mannequin
Number of subjects: 75
Study: 35392979

Group type: EXPERIMENTAL
Intervention: Reactive Case Detection (RCD)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: targeted Mass Drug Administration (tMDA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 48
Study: 34091276

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined CPT and Cognitive Symptom Management and Rehabilitation Therapy (SMART-CPT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CPT and SMART-CPT
Number of subjects: 100
Study: 36343979

Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose (FDI)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both FDI and FCM
Number of subjects: 97
Study: 32985396

Group type: EXPERIMENTAL
Intervention: Group activity with Paro (robotic seal) for 30 minutes twice a week over 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (Control group)
Number of subjects: 60
Study: 35062832

Group type: EXPERIMENTAL
Intervention: RT (Resistance Training)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: RT+BFR (Resistance Training with Blood Flow Restriction)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study: 33242153

Group type: EXPERIMENTAL
Intervention: Automated manikin feedback
Number of subjects: 56

Group type: COMPARATOR
Intervention: Instructor feedback
Number of subjects: 56
Study: 32621874

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU weekly for the first month, followed by 2000 IU daily)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 4000
Study: 36484691

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response Cognitive Behavioral Therapy for Chronic Pain (IVR CBT-CP)
Number of subjects: 108
Study: 35322340

Group type: EXPERIMENTAL
Intervention: Active tDCS (n=13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham tDCS (n=13)
Number of subjects: 26
Study: 32669943

Group type: EXPERIMENTAL
Intervention: Chart review (gold standard definition of recurrence)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Definition of recurrence: 2 or more cancer diagnosis codes 10 or more months from the diagnosis date
Number of subjects: 200
Study: 35343942

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus ESHAP
Number of subjects: 150

Group type: COMPARATOR
Intervention: ESHAP alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 150
Study: 33637350

Group type: EXPERIMENTAL
Intervention: Fitbit intervention with gamification and social support
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fitbit intervention
Number of subjects: 24
Study: 33032770

Group type: EXPERIMENTAL
Intervention: IV golimumab 2 mg/kg at weeks 0, 4, and 12, and every 8 weeks thereafter
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo at weeks 0, 4, and 12
Number of subjects: 208
Study: 36287604

Group type: EXPERIMENTAL
Intervention: Digital SDM intervention for 6 months
Number of subjects: 194

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 194
Study: 34492632

Group type: EXPERIMENTAL
Intervention: Targeted Early Palliative Care (EPC)
Number of subjects: 116

Group type: COMPARATOR
Intervention: No Early Palliative Care (EPC)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Screen-negative patients
Number of subjects: 116
Study: 32641967

Group type: EXPERIMENTAL
Intervention: Plantago ovata mucilage eye drop, 4 times a day for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo eye drop, 4 times a day for 6 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Plantago ovata mucilage eye drop
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo eye drop
Number of subjects: 60
Study: 36184697

Group type: EXPERIMENTAL
Intervention: Mepolizumab 24 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Reslizumab 0.8 mg/kg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mepolizumab (3-24 mg) and Reslizumab (0.1-0.8 mg/kg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Model-based simulations
Number of subjects: 72
Study: 34751628

Group type: EXPERIMENTAL
Intervention: Unattended blood pressure measurement (121.7/68.6 mmHg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Unattended blood pressure measurement
Number of subjects: 62

Group type: COMPARATOR
Intervention: Attended blood pressure measurement
Number of subjects: 62
Study: 35345367

Group type: EXPERIMENTAL
Intervention: Single application of 85% TCA (n=26)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Twice application of 85% TCA (n=27)
Number of subjects: 53
Study: 36161779

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 505
Study: 34098394

Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum block (QLB) combined with local infiltration analgesia (LIA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 80
Study: 32584285

Group type: EXPERIMENTAL
Intervention: 660-nm diode laser applied for 2 minutes
Number of subjects: 50

Group type: COMPARATOR
Intervention: No application of 660-nm diode laser
Number of subjects: 50
Study: 36181056

Group type: EXPERIMENTAL
Intervention: Curcuminoids at 1500 mg per day for 3 days before and 2 days after the procedure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Curcuminoids
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Curcuminoids and Control (placebo)
Number of subjects: 60
Study: 34143568

Group type: EXPERIMENTAL
Intervention: Mandala colouring for 30 min/day for six consecutive days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 70
Study: 35072422

Group type: EXPERIMENTAL
Intervention: Endocrown group
Number of subjects: 670

Group type: COMPARATOR
Intervention: Post and core crown group
Number of subjects: 670
Study: 33821899

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg orally daily for 3 years)
Number of subjects: 2526

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2526

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 2526
Study: 36217848

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination (2nd dose)
Number of subjects: 0
Study: 32928161

Group type: EXPERIMENTAL
Intervention: 60-min Football activity
Number of subjects: 36

Group type: COMPARATOR
Intervention: 60-min seated rest
Number of subjects: 36
Study: 33740090

Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 33153434

Group type: EXPERIMENTAL
Intervention: Complementary feeding behavior change communication delivered through women development army leaders for 9 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual health care (Control)
Number of subjects: 16
Study: 36372995

Group type: EXPERIMENTAL
Intervention: Integrated PIVCs
Number of subjects: 1759

Group type: COMPARATOR
Intervention: Nonintegrated PIVCs
Number of subjects: 1759
Study: 33421560

Group type: EXPERIMENTAL
Intervention: Subcutaneous tissue disinfection with povidone-iodine solution
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no additional disinfection)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Subcutaneous disinfection protocol
Number of subjects: 108
Study: 32020438

Group type: EXPERIMENTAL
Intervention: SEQ tremelimumab 75 mg IV over 1 h followed by durvalumab 1500 mg IV over 1 h q4wks
Number of subjects: 14

Group type: COMPARATOR
Intervention: CON administration of durvalumab and tremelimumab over 1 h
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both SEQ and CON
Number of subjects: 14
Study: 35753884

Group type: EXPERIMENTAL
Intervention: Spinal Manipulation (SMa)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Spinal Mobilization (SMo)
Number of subjects: 26
Study: 34847581

Group type: EXPERIMENTAL
Intervention: Manufacturer first-fit (FF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Aided sound-field thresholds (ASFT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Skull simulator/DSL-BCD
Number of subjects: 15
Study: 35788774

Group type: COMPARATOR
Intervention: Short-interval group
Number of subjects: 141

Group type: COMPARATOR
Intervention: Long-interval group
Number of subjects: 141
Study: 33009066

Group type: EXPERIMENTAL
Intervention: BoNTA/EMDA (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intrasphincteric BoNTA injection (n = 30)
Number of subjects: 60
Study: 36048997

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 80
Study: 33480241

Group type: EXPERIMENTAL
Intervention: HCM (1.5, 3.0 and 6.0 g/kg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HCM (6.0 g/kg)
Number of subjects: 72
Study: 32046754

Group type: EXPERIMENTAL
Intervention: Transcutaneous Tibial Nerve Stimulation (TTNS)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Parasacral Transcutaneous Electrical Stimulation (PTES)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 34668569

Group type: EXPERIMENTAL
Intervention: Springboard Beyond Cancer eHealth self-management program
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Moderate-to-high engagement in the text and/or web intervention (n = 30)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (n = 88)
Number of subjects: 176
Study: 33892682

Group type: EXPERIMENTAL
Intervention: PREVENTURE programme targeting impulsivity, sensation-seeking, negative thoughts, and anxiety.
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: PREVENTURE programme
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 700
Study: 32174130

Group type: EXPERIMENTAL
Intervention: Low-Attenuation Plaque Burden
Number of subjects: 1769

Group type: EXPERIMENTAL
Intervention: Coronary Artery Calcium Score
Number of subjects: 1769

Group type: EXPERIMENTAL
Intervention: Obstructive Coronary Artery Disease
Number of subjects: 1769

Group type: EXPERIMENTAL
Intervention: Low-Attenuation Plaque Burden >4%
Number of subjects: 1769
Study: 35623754

Group type: EXPERIMENTAL
Intervention: Suicide attempters overall
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: Suicide attempters within 5 years
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: Suicide attempters after 5 years
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: Violent method attempters (VA)
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: Repeated suicide attempters (RA) and high intent attempters (HS)
Number of subjects: 1039
Study: 34951682

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT) at 60–70% HRpeak for 30 min/session (n = 34, 150 min/week)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 4 × 4 min bouts at 85–95% HRpeak (n = 34, 38 min/session, 114 min/week)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 1 × 4 min bout at 85–95% HRpeak (n = 31, 17 min/session, 51 min/week)
Number of subjects: 99
Study: 32981268

Group type: EXPERIMENTAL
Intervention: Urtica Dioica root extract (UDE) 450 mg day‐1 for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study: 34396685

Group type: EXPERIMENTAL
Intervention: SKH app intervention (experimental group I)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Paper-based intervention (experimental group II)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual intervention (control group)
Number of subjects: 116
Study: 32414368

Group type: EXPERIMENTAL
Intervention: Educational eHealth tool
Number of subjects: 286

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 286
Study: 35565243

Group type: EXPERIMENTAL
Intervention: Naldemedine (NAL) 0.2 mg, once daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Magnesium Oxide (MgO) 500 mg, thrice daily
Number of subjects: 120
Study: 34936275

Group type: EXPERIMENTAL
Intervention: Umbilical moxibustion (7 moxa cones, 2 times a week for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TCM health guidance (diet and exercise)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Umbilical moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: TCM health guidance
Number of subjects: 60
Study: 36454569

Group type: EXPERIMENTAL
Intervention: Esketamine infusion (0.3 mg/kg/h)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 183
Study: 34857076

Group type: EXPERIMENTAL
Intervention: Abdominal binder
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no binder)
Number of subjects: 40
Study: 32461015

Group type: EXPERIMENTAL
Intervention: TaTME
Number of subjects: 64

Group type: COMPARATOR
Intervention: LaTME
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: TaTME and LaTME
Number of subjects: 64
Study: 32026173

Group type: EXPERIMENTAL
Intervention: Robot-mediated response to joint attention intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 34562067

Group type: COMPARATOR
Intervention: Single dose of 200-600 mg of RO7049389
Number of subjects: 52

Group type: COMPARATOR
Intervention: Multiple doses of 200-400 mg of RO7049389
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (single ascending dose)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (multiple ascending doses)
Number of subjects: 52
Study: 33484934

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg daily subcutaneous injection)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (routine high risk pregnancy prenatal care)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control
Number of subjects: 125

Group type: COMPARATOR
Intervention: Enoxaparin and Control
Number of subjects: 125
Study: 32356084

Group type: EXPERIMENTAL
Intervention: Condition 1: Research suggesting SO has biogenetic origins
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Condition 2: Research suggesting SO is socially constructed
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Condition 3: Research suggesting SO is biogenetic and socially constructed
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 201
Study: 34718173

Group type: EXPERIMENTAL
Intervention: ACP video decision support tool (5-minute video)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Verbal narrative of goals of care
Number of subjects: 59
Study: 34127299

Group type: EXPERIMENTAL
Intervention: School-based HPV vaccination program
Number of subjects: 22
Study: 33371157

Group type: EXPERIMENTAL
Intervention: Magnetic stimulation of HT7 acupoint (30 times, 2 times/day, 5 times/week for 20 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Behavioral cognitive therapy technology (sleep hygiene and cognitive therapy)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Healthy control group (no intervention)
Number of subjects: 72
Study: 32842825

Group type: EXPERIMENTAL
Intervention: LSD 20 µg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 32341356

Group type: EXPERIMENTAL
Intervention: Vitamin E (alpha-tocopherol) 400 IU
Number of subjects: 187
Study: 36196515

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) using a 940 nm diode laser before dental injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no laser) quadrant
Number of subjects: 30
Study: 33629647

Group type: EXPERIMENTAL
Intervention: 11-week exercise intervention
Number of subjects: 26
Study: 34957988

Group type: EXPERIMENTAL
Intervention: Tertiary rehabilitation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standardized treatment
Number of subjects: 96
Study: 34652243

Group type: EXPERIMENTAL
Intervention: LSVT-LOUD
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 44
Study: 35652771

Group type: EXPERIMENTAL
Intervention: Rotator Interval (RI) approach
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Posterior Capsule (PC) approach
Number of subjects: 90
Study: 34140425

Group type: EXPERIMENTAL
Intervention: Function-focused care
Number of subjects: 794

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 794